LONDON BRIEFING: Barclays buys Tesco's retail banking business
(Alliance News) - Stocks in London are called to open higher on Friday, closing off a busy corporate week.
Read moreFri, 16th Apr 2021 12:04
(Alliance News) - Stocks in London are called to open higher on Friday, closing off a busy corporate week.
Read more(Alliance News) - London's FTSE 100 ended lower on Thursday, with mixed corporate updates keeping a lid on enthusiasm, while in New York the S&P 500 has the 5,000 point mark in touching distance.
Read more(Sharecast News) - London markets experienced a downturn in trading on Thursday, with stocks relinquishing earlier gains as investors processed a decrease in jobless claims in the United States.
Read more(Alliance News) - Stock prices in London were mixed at midday Thursday, as markets struggled to find direction amid a mixed wave of corporate updates and earnings.
Read more(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.
Read more(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.
Read more(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.
Read more(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.
Read more(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.
Read more(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.
Read moreFriday 2 February | |
YouGov PLC | Trading Statement |
Monday 5 February | |
Home REIT PLC | Trading Statement |
Porvair PLC | Full Year Results |
Trident Royalties PLC | Trading Statement |
Vodafone Group PLC | Trading Statement |
Tuesday 6 February | |
Alumasc Group PLC | Half Year Results |
BP PLC | Full Year Results |
Filtronic PLC | Half Year Results |
Mattioli Woods PLC | Half Year Results |
Renishaw PLC | Half Year Results |
Virgin Money UK PLC | Trading Statement |
Wednesday 7 February | |
Ashmore Group PLC | Half Year Results |
Barratt Developments PLC | Half Year Results |
HydrogenOne Capital Growth PLC | Trading Statement |
Phoenix Spree Deutschland Ltd | Trading Statement |
PZ Cussons PLC | Half Year Results |
Smurfit Kappa Group PLC | Full Year Results |
UK Commercial Property REIT Ltd | Trading Statement |
Thursday 8 February | |
Anglo American PLC | Trading Statement |
AstraZeneca PLC | Full Year Results |
British American Tobacco PLC | Full Year Results |
Compass Group PLC | Trading Statement |
Redrow PLC | Half Year Results |
SSE PLC | Trading Statement |
Unilever PLC | Full Year Results |
Comments and questions to newsroom@alliancenews.com | |
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional. | |
Copyright 2024 Alliance News Ltd. All Rights Reserved. |
(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.
Read moreFRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.
Read more(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.
Read moreFTSE 100 down 0.5%, FTSE 250 flat
*Read more